ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

NCT06816992 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
EGFR Exon 20 Insertion Mutations
NSCLC
EGFR-mutated NSCLC

Interventions

DRUG: ORIC-114 Dose 1 + amivantamab
DRUG: ORIC-114 Dose 2 + amivantamab
DRUG: ORIC-114 Dose 3 + amivantamab

Sponsor

ORIC Pharmaceuticals

Collaborators

[object Object]